Satralizumab Shows Clinically Meaningful Improvements in TED

Phase III trials of Genentech's satralizumab demonstrated clinically meaningful improvements in thyroid eye disease (TED) symptoms, supporting its potential FDA approval as a new disease-specific treatment with a favourable safety profile.

This Wire brief sits within Fusion42's coverage of Medtech.